Perfusion and Hypoxia Evaluation in Tumors Using 18F-FDG PET/CT
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03373994|
Recruitment Status : Recruiting
First Posted : December 14, 2017
Last Update Posted : August 31, 2018
|Condition or disease||Intervention/treatment|
|Perfusion and Hypoxia||Diagnostic Test: 18F-FDG PET/CT initial-time imaging Diagnostic Test: 18F-FDG PET/CT balanced-time imaging|
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Tumor Perfusion and Hypoxia Evaluation and Comparation in 18F-FDG PET/CT|
|Actual Study Start Date :||November 1, 2016|
|Estimated Primary Completion Date :||December 31, 2018|
|Estimated Study Completion Date :||January 31, 2019|
18F-FDG PET/CT initial-time imaging
PET/CT imaging was underwent 5min after 18F-FDG injection.
Diagnostic Test: 18F-FDG PET/CT initial-time imaging
18F-FDG intravenous bolus injection after a fasting perid of more than 6 hours, simultaneously,PET/CT imaging using one bed lasting 5 minutes was underwent.
18F-FDG PET/CT balanced-time imaging
PET/CT imaging was underwent 60min after 18F-FDG injection.
Diagnostic Test: 18F-FDG PET/CT balanced-time imaging
18F-FDG intravenous injection after a fasting perid of more than 6 hours. After 60 minutes, PET/CT imaging using 6-7 bed positions each lasting 2 minutes was underwent.
- Correlation of the distribution of FDG between initial-time and balanced-time PET/CT [ Time Frame: 2018.1 ]Initial-time and balanced-time PET/CT imaging were registrated using PET/CT Compare software in GE AW4.6 workstation. FDG distribution was evaluated in each imaging and the correlation was evaluated.
- SUVs in initial-time and balanced-time PET/CT [ Time Frame: 2018.1 ]the SUVmax and SUVmean was calculated in well-perfused area and hypoxia area in tumors using PET/CT Render software in GE AW4.6 workstation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03373994
|Contact: Yingying Sun, Dremail@example.com|
|Harbin, Heil, China, 150028|
|Contact: Yingying Sun, Dr 13936447513 firstname.lastname@example.org|
|Study Chair:||Baozhong Shen, Dr||The Fourth Hospital of Harbin Medical University|